• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

如何缓解囊性纤维化患者的胃肠道症状?一项国际定性调查。

How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey.

机构信息

Child Health Obstetrics and Gynaecology, University of Nottingham, Nottingham, UK

Child Health Obstetrics and Gynaecology, University of Nottingham, Nottingham, UK.

出版信息

BMJ Open Respir Res. 2020 Sep;7(1). doi: 10.1136/bmjresp-2020-000614.

DOI:10.1136/bmjresp-2020-000614
PMID:32900780
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7478045/
Abstract

INTRODUCTION

Relieving gastrointestinal (GI) symptoms was identified as a 'top ten' priority by our James Lind Alliance Priority Setting Partnership in cystic fibrosis (CF). We conducted an online survey to find out more about the effect of GI symptoms in CF.

METHODS

We co-produced an online survey distributed to the CF community via web-based platforms. The survey consisted of open and closed questions designed to help us learn more about the effects of GI symptoms for people with CF (pwCF). We analysed the data using descriptive statistics and thematic analysis. We promoted the survey via social media and web-based platforms which allowed respondents from any country to take part. Our participants came from the CF community, including: adults and children with CF, parents and close family of pwCF and healthcare professionals (HCPs) working with pwCF.

RESULTS

There were 276 respondents: 90 (33%) pwCF, 79 (29%) family, 107 (39%) HCPs. The most commonly reported symptoms by lay respondents were stomach cramps/pain, bloating and a 'combination of symptoms'. The top three symptoms that HCPs said were reported to them were reduced appetite, bloating and constipation. Almost all (94% (85/90)) HCPs thought medications helped to relieve GI symptoms but only 58% (82/141) of lay respondents agreed.

CONCLUSIONS

Our survey has shown that GI symptoms among our participants are prevalent and intrude on daily lives of pwCF. There is a need for well-designed clinical studies to provide better evidence for management of GI symptoms and complications.

摘要

简介

胃肠道(GI)症状缓解被我们的詹姆斯林德联盟优先事项设定伙伴关系确定为囊性纤维化(CF)的“十大”优先事项之一。我们进行了一项在线调查,以了解更多关于 CF 中 GI 症状的影响。

方法

我们共同制作了一份在线调查,通过网络平台分发给 CF 社区。该调查包括开放式和封闭式问题,旨在帮助我们更多地了解 CF 患者(pwCF)的 GI 症状的影响。我们使用描述性统计和主题分析来分析数据。我们通过社交媒体和网络平台宣传调查,允许来自任何国家的受访者参与。我们的参与者来自 CF 社区,包括:患有 CF 的成年人和儿童、pwCF 的父母和近亲以及与 pwCF 合作的医疗保健专业人员(HCPs)。

结果

共有 276 名受访者:90 名(33%)pwCF、79 名(29%)家属、107 名(39%)HCPs。非专业人员报告的最常见症状是胃痛/腹痛、腹胀和“多种症状”。HCPs 报告给他们的前三种症状是食欲下降、腹胀和便秘。几乎所有(94%(85/90))HCPs 认为药物有助于缓解 GI 症状,但只有 58%(82/141)的非专业人员同意。

结论

我们的调查表明,参与者的 GI 症状普遍存在,并干扰了 pwCF 的日常生活。需要进行精心设计的临床研究,为 GI 症状和并发症的管理提供更好的证据。

相似文献

1
How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey.如何缓解囊性纤维化患者的胃肠道症状?一项国际定性调查。
BMJ Open Respir Res. 2020 Sep;7(1). doi: 10.1136/bmjresp-2020-000614.
2
A grumbling concern: A survey of gastrointestinal symptoms in cystic fibrosis in the modulator era.一个令人担忧的问题:调节剂时代囊性纤维化患者胃肠道症状的调查
NIHR Open Res. 2024 Feb 5;3:18. doi: 10.3310/nihropenres.13384.1. eCollection 2023.
3
Adapting the James Lind Alliance priority setting process to better support patient participation: an example from cystic fibrosis.调整詹姆斯·林德联盟的优先事项设定流程以更好地支持患者参与:来自囊性纤维化的一个例子。
Res Involv Engagem. 2019 Aug 20;5:24. doi: 10.1186/s40900-019-0159-x. eCollection 2019.
4
What effective ways of motivation, support and technologies help people with cystic fibrosis improve and sustain adherence to treatment?有哪些有效的激励、支持和技术方法可以帮助囊性纤维化患者改善并坚持治疗?
BMJ Open Respir Res. 2020 Aug;7(1). doi: 10.1136/bmjresp-2020-000601.
5
Can exercise replace airway clearance techniques in cystic fibrosis? A survey of patients and healthcare professionals.运动能否替代囊性纤维化患者的气道廓清技术?一项对患者和医疗保健专业人员的调查。
J Cyst Fibros. 2020 Jul;19(4):e19-e24. doi: 10.1016/j.jcf.2019.10.026. Epub 2019 Nov 15.
6
Cystic fibrosis and fat malabsorption: Pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective CFTR modulator therapy.囊性纤维化和脂肪吸收不良:囊性纤维化胃肠道的病理生理学和高效 CFTR 调节剂治疗的影响。
Nutr Clin Pract. 2024 Apr;39 Suppl 1:S57-S77. doi: 10.1002/ncp.11122.
7
Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis.多中心前瞻性研究显示囊性纤维化患者胃肠道症状负担高。
J Cyst Fibros. 2023 Mar;22(2):266-274. doi: 10.1016/j.jcf.2022.10.006. Epub 2022 Oct 29.
8
A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders.使用已在其他胃肠道疾病中验证过的工具,在成年囊性纤维化患者中检测到慢性胃肠道症状的高发率。
United European Gastroenterol J. 2019 Aug;7(7):881-888. doi: 10.1177/2050640619841545.
9
Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis.糖尿病与成年囊性纤维化患者胃肠道症状负担增加有关。
J Cyst Fibros. 2023 Mar;22(2):275-281. doi: 10.1016/j.jcf.2023.01.010. Epub 2023 Jan 27.
10
Barriers implementing infection prevention and control experienced by healthcare workers, people with CF and parents.医护人员、CF 患者和家长在实施感染预防和控制方面所面临的障碍。
J Cyst Fibros. 2022 Mar;21(2):309-315. doi: 10.1016/j.jcf.2021.07.009. Epub 2021 Sep 11.

引用本文的文献

1
CF Tummy Tracker: A Cystic Fibrosis-Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom Burden.囊性纤维化腹部追踪器:一种针对囊性纤维化患者报告的每日胃肠道症状负担的特定结局指标。
Mayo Clin Proc Digit Health. 2025 Mar 3;3(2):100203. doi: 10.1016/j.mcpdig.2025.100203. eCollection 2025 Jun.
2
Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.依伐卡托-替扎卡托-艾列卡托、替扎卡托-依伐卡托和鲁玛卡托-依伐卡托治疗囊性纤维化:系统评价与经济学评估
Health Technol Assess. 2025 May;29(19):1-111. doi: 10.3310/CPLD8546.
3

本文引用的文献

1
Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging.通过磁共振成像评估囊性纤维化患者餐后胃肠功能和转运的变化。
J Cyst Fibros. 2021 Jul;20(4):591-597. doi: 10.1016/j.jcf.2020.06.004. Epub 2020 Jun 16.
2
Probiotics for people with cystic fibrosis.用于囊性纤维化患者的益生菌。
Cochrane Database Syst Rev. 2020 Jan 22;1(1):CD012949. doi: 10.1002/14651858.CD012949.pub2.
3
A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders.
The Dutch Gastrointestinal Symptom Tracker for People With Cystic Fibrosis: Associations With Anxiety, Depression, and Health-Related Quality of Life.
荷兰囊性纤维化患者胃肠道症状追踪器:与焦虑、抑郁及健康相关生活质量的关联
Pediatr Pulmonol. 2025 Mar;60(3):e71021. doi: 10.1002/ppul.71021.
4
Collaboration between registered dietitians and gastroenterologists in cystic fibrosis care: Results of an international cross-sectional survey.注册营养师与胃肠病学家在囊性纤维化护理中的合作:一项国际横断面调查结果
Nutr Clin Pract. 2025 Feb;40(1):195-208. doi: 10.1002/ncp.11219. Epub 2024 Oct 8.
5
A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes: a pilot study.一项关于tezacaftor-ivacaftor治疗囊性纤维化肠道功能障碍并以磁共振成像(MRI)结果为指标的随机交叉试验:一项试点研究。
NIHR Open Res. 2024 Mar 19;3:65. doi: 10.3310/nihropenres.13510.2. eCollection 2023.
6
Presentation, characteristics and management of obstructive intestinal conditions in cystic fibrosis.囊性纤维化中梗阻性肠道疾病的表现、特征及管理
Frontline Gastroenterol. 2024 Jan 6;15(3):222-227. doi: 10.1136/flgastro-2023-102533. eCollection 2024 May.
7
Scoring Abdominal Symptoms in People with Cystic Fibrosis.对囊性纤维化患者的腹部症状进行评分
J Clin Med. 2024 Mar 13;13(6):1650. doi: 10.3390/jcm13061650.
8
The current state of gastrointestinal motility evaluation in cystic fibrosis: a comprehensive literature review.囊性纤维化患者胃肠动力评估的现状:一项全面的文献综述
Transl Gastroenterol Hepatol. 2023 Dec 6;9:10. doi: 10.21037/tgh-23-59. eCollection 2024.
9
A grumbling concern: A survey of gastrointestinal symptoms in cystic fibrosis in the modulator era.一个令人担忧的问题:调节剂时代囊性纤维化患者胃肠道症状的调查
NIHR Open Res. 2024 Feb 5;3:18. doi: 10.3310/nihropenres.13384.1. eCollection 2023.
10
Prebiotics for people with cystic fibrosis.用于囊性纤维化患者的益生元。
Cochrane Database Syst Rev. 2023 Sep 27;9(9):CD015236. doi: 10.1002/14651858.CD015236.pub2.
使用已在其他胃肠道疾病中验证过的工具,在成年囊性纤维化患者中检测到慢性胃肠道症状的高发率。
United European Gastroenterol J. 2019 Aug;7(7):881-888. doi: 10.1177/2050640619841545.
4
Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation.依伐卡托(Ivacaftor)对囊性纤维化跨膜电导调节因子(CFTR)的调节作用对肠道微生物群和肠道炎症的影响。
Sci Rep. 2018 Dec 13;8(1):17834. doi: 10.1038/s41598-018-36364-6.
5
Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis.根据来自地理分布不同的欧洲人群的家族研究以及囊性纤维化的早期传播,估计 p.(Phe508del)的年龄。
Eur J Hum Genet. 2018 Dec;26(12):1832-1839. doi: 10.1038/s41431-018-0234-z. Epub 2018 Aug 8.
6
Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.囊性纤维化的校正剂(针对II类CFTR突变的特异性疗法)
Cochrane Database Syst Rev. 2018 Aug 2;8(8):CD010966. doi: 10.1002/14651858.CD010966.pub2.
7
Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis.囊性纤维化患者患胃肠道癌症的风险:系统评价和荟萃分析。
Lancet Oncol. 2018 Jun;19(6):758-767. doi: 10.1016/S1470-2045(18)30188-8. Epub 2018 Apr 26.
8
The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers.由囊性纤维化患者和医疗保健提供者组成的合作伙伴关系制定的囊性纤维化十大研究重点。
Thorax. 2018 Apr;73(4):388-390. doi: 10.1136/thoraxjnl-2017-210473. Epub 2017 Aug 4.
9
Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings.囊性纤维化的腹部症状及其与基因型、病史、临床和实验室检查结果的关系。
PLoS One. 2017 May 4;12(5):e0174463. doi: 10.1371/journal.pone.0174463. eCollection 2017.
10
Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation.CFTR调节剂对囊性纤维化合并G551D突变患者肠道pH值、运动功能及临床结局的影响
Clin Transl Gastroenterol. 2017 Mar 16;8(3):e81. doi: 10.1038/ctg.2017.10.